Abstract
BackgroundImmune checkpoint inhibitors (ICIs) are now approved for several cancer types due to superior outcomes compared to chemotherapy. PD-1/PD-L1 and CTLA-4 inhibitors reactivate T-cell mediated anti-tumor immunity but may also...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
